Abera Bioscience AB, 2141 Uppsala, Sweden.
Department of Molecular Microbiology, Amsterdam Institute of Molecular and Life Sciences (AIMMS), Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Int J Mol Sci. 2022 Jul 2;23(13):7393. doi: 10.3390/ijms23137393.
A licensed vaccine is not yet available. Recombinant major outer membrane protein (-MOMP), the most abundant constituent of the chlamydial outer membrane complex, is considered the most attractive candidate for subunit-based vaccine formulations. Unfortunately, -MOMP is difficult to express in its native structure in the outer membrane (OM). Here, by co-expression of the Bam complex, we improved the expression and localization of recombinant -MOMP in the OM. Under these conditions, recombinant -MOMP appeared to assemble into a β-barrel conformation and express domains at the cell surface indicative of correct folding. The data indicate that limited availability of the Bam complex can be a bottleneck for the production of heterologous OM vaccine antigens, information that is also relevant for strategies aimed at producing recombinant OMV-based vaccines.
一种许可疫苗尚未上市。重组主要外膜蛋白（-MOMP）是衣原体外膜复合物中最丰富的成分，被认为是基于亚单位疫苗制剂最有吸引力的候选物。不幸的是，-MOMP 在外膜（OM）中很难以其天然结构表达。在这里，通过 Bam 复合物的共表达，我们提高了重组 -MOMP 在 OM 中的表达和定位。在这些条件下，重组 -MOMP 似乎组装成β-桶构象，并在细胞表面表达出正确折叠的结构域。这些数据表明 Bam 复合物的有限可用性可能是生产异源 OM 疫苗抗原的瓶颈，这一信息对于旨在生产基于重组 OMV 的疫苗的策略也很重要。
